Centre hospitalier de l'Université de Montréal (CHUM) — Biomedical Watch V2

Traitements16programmes

Essais8liés

Publications6liées

SourceDBlocale

Traitements

16

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Convertible Plasma JetThe goal of this clinical trial is to test the safety of the use of non-thermal plasma (NTP, an ionized gas) on the tumor bed after the removal of the tumor in breast cancer patients. The main questions it aims to answer are: * To determine the safe and tolerable dose of NTP in patients with breast cancer; * To assess the safety and tolerability of NTP; * To assess the cosmetic effects of NTP treatment in patients with breast cancer. Participants will receive one treatment of the tumor bed after the removal of their breast tumor.	Cancer	Non applicable	À vérifier	Canada	À vérifier
Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) PatientsDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	Non applicable	À vérifier	Canada	À vérifier
EUS-guided celiac plexus neurolysisPancreatic cancer presents with pain in the majority of cases. Destruction of the celiac ganglia by ultrasound guided injection of sclerosing agents such as alcohol is sometimes used for pain that no longer responds to treatment with narcotics. The investigators compare standard narcotic treatment to celiac plexus alcohol injection (celiac plexus neurolysis) and do so in patients with early, mild pain to see if celiac plexus neurolysis is more effective than narcotics and prevents escalating narcotic use.	Cancer	Phase 3	Traitement symptomatique	Canada	À vérifier
No prophylactic defect closureThe goal of this clinical trial is to compare adverse even rates after EMR for large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions, LSLs) when performing complete or no defect closure. It will also evaluate lesion recurrence after EMR for large colorectal LSLs. The hypothesis is that performing complete defect closure following EMR of large colorectal LSLs will result in lower rates of adverse events compared to cases where no defect closure is performed. For participants with planned EMR, endoscopists will perform EMRs as per standard of care and: * prophylactic defect closure will either not be performed (control group), or will be performed (experimental group); * then, patients will be called between 14 and 44 days after EMR to assess for possible adverse events, and electronic medical files will be verified for emergency room visits and healthcare received for an adverse event; * finally, patients will undergo follow-up colonoscopy 6 months and 18 months after randomization.	Cancer	Non applicable	À vérifier	Canada	À vérifier
Post-operative radiotherapyThis study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery. The primary objective is to compare event-free survival (EFS) between patients receiving PORT targeting involved lymph node regions and those without PORT. Secondary and tertiary endpoints include overall survival, locoregional and distant control, toxicity, and quality of life. The phase II randomized trial will enroll 118 patients, stratifying by adjuvant immunotherapy use, with follow-up extending up to 5 years. Statistical analysis aims to detect a 15% improvement in 2-year EFS, with a total study duration of 7 years.	Cancer	Phase 2	À vérifier	Canada	À vérifier
Prophylactic defect closureThe goal of this clinical trial is to compare adverse even rates after EMR for large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions, LSLs) when performing complete or no defect closure. It will also evaluate lesion recurrence after EMR for large colorectal LSLs. The hypothesis is that performing complete defect closure following EMR of large colorectal LSLs will result in lower rates of adverse events compared to cases where no defect closure is performed. For participants with planned EMR, endoscopists will perform EMRs as per standard of care and: * prophylactic defect closure will either not be performed (control group), or will be performed (experimental group); * then, patients will be called between 14 and 44 days after EMR to assess for possible adverse events, and electronic medical files will be verified for emergency room visits and healthcare received for an adverse event; * finally, patients will undergo follow-up colonoscopy 6 months and 18 months after randomization.	Cancer	Non applicable	À vérifier	Canada	À vérifier
SBRTImmunotherapy targeting the PD-1/PD-L1 pathway had previously been shown to be efficacious in the treatment of patients with metastatic head and neck squamous cell carcinomas. Stereotactic Body Radiotherapy (SBRT) to metastatic lesions causes localized cancer cell killing and the release of cancer cell debris, which could stimulate the immune system in the presence of immunotherapy. The purpose of this study is to assess the tolerability and efficacy of combining Durvalumab (MEDI4736), Tremelimumab and SBRT in controlling cancer progression. SBRT will be administered to patients while they are receiving Durvalumab and Tremelimumab.	Cancer	Phase 1/2	Ralentissement de la progression	Canada	À vérifier
Standard-of-care surgeryThe SAVED LUNG study is a pilot Phase I trial evaluating safety and feasibility of observation versus standard-of-care surgery in operable Stage II-III (excluding N3) NSCLC patients (PD-L1 ≥50%) who achieve complete clinical response following neoadjuvant platinum-doublet chemotherapy and immunotherapy. Participants are randomized to observation or surgery after rigorous restaging, with primary endpoints focusing on safety and feasibility. Secondary objectives include rates of cross-over to surgery, event-free survival, and overall survival, while exploratory endpoints examine ctDNA clearance and its association with clinical response.	Cancer	Phase 1	À vérifier	Canada	À vérifier
TremelimumabImmunotherapy targeting the PD-1/PD-L1 pathway had previously been shown to be efficacious in the treatment of patients with metastatic head and neck squamous cell carcinomas. Stereotactic Body Radiotherapy (SBRT) to metastatic lesions causes localized cancer cell killing and the release of cancer cell debris, which could stimulate the immune system in the presence of immunotherapy. The purpose of this study is to assess the tolerability and efficacy of combining Durvalumab (MEDI4736), Tremelimumab and SBRT in controlling cancer progression. SBRT will be administered to patients while they are receiving Durvalumab and Tremelimumab.	Cancer	Phase 1/2	Ralentissement de la progression	Canada	À vérifier
Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) PatientsDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé.	Sclérose latérale amyotrophique	Non applicable	À vérifier	Canada	À vérifier
Standard-of-care surgeryThe SAVED LUNG study is a pilot Phase I trial evaluating safety and feasibility of observation versus standard-of-care surgery in operable Stage II-III (excluding N3) NSCLC patients (PD-L1 ≥50%) who achieve complete clinical response following neoadjuvant platinum-doublet chemotherapy and immunotherapy. Participants are randomized to observation or surgery after rigorous restaging, with primary endpoints focusing on safety and feasibility. Secondary objectives include rates of cross-over to surgery, event-free survival, and overall survival, while exploratory endpoints examine ctDNA clearance and its association with clinical response.	Cancer	Phase 1	À vérifier	Canada	À vérifier
SBRTImmunotherapy targeting the PD-1/PD-L1 pathway had previously been shown to be efficacious in the treatment of patients with metastatic head and neck squamous cell carcinomas. Stereotactic Body Radiotherapy (SBRT) to metastatic lesions causes localized cancer cell killing and the release of cancer cell debris, which could stimulate the immune system in the presence of immunotherapy. The purpose of this study is to assess the tolerability and efficacy of combining Durvalumab (MEDI4736), Tremelimumab and SBRT in controlling cancer progression. SBRT will be administered to patients while they are receiving Durvalumab and Tremelimumab.	Cancer	Phase 1/2	Ralentissement de la progression	Canada	À vérifier
EUS-guided celiac plexus neurolysisPancreatic cancer presents with pain in the majority of cases. Destruction of the celiac ganglia by ultrasound guided injection of sclerosing agents such as alcohol is sometimes used for pain that no longer responds to treatment with narcotics. The investigators compare standard narcotic treatment to celiac plexus alcohol injection (celiac plexus neurolysis) and do so in patients with early, mild pain to see if celiac plexus neurolysis is more effective than narcotics and prevents escalating narcotic use.	Cancer	Phase 3	Traitement symptomatique	Canada	À vérifier
Post-operative radiotherapyThis study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery. The primary objective is to compare event-free survival (EFS) between patients receiving PORT targeting involved lymph node regions and those without PORT. Secondary and tertiary endpoints include overall survival, locoregional and distant control, toxicity, and quality of life. The phase II randomized trial will enroll 118 patients, stratifying by adjuvant immunotherapy use, with follow-up extending up to 5 years. Statistical analysis aims to detect a 15% improvement in 2-year EFS, with a total study duration of 7 years.	Cancer	Phase 2	À vérifier	Canada	À vérifier
Convertible Plasma JetThe goal of this clinical trial is to test the safety of the use of non-thermal plasma (NTP, an ionized gas) on the tumor bed after the removal of the tumor in breast cancer patients. The main questions it aims to answer are: * To determine the safe and tolerable dose of NTP in patients with breast cancer; * To assess the safety and tolerability of NTP; * To assess the cosmetic effects of NTP treatment in patients with breast cancer. Participants will receive one treatment of the tumor bed after the removal of their breast tumor.	Cancer	Non applicable	Traitement symptomatique	Canada	À vérifier
Prophylactic defect closureThe goal of this clinical trial is to compare adverse even rates after EMR for large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions, LSLs) when performing complete or no defect closure. It will also evaluate lesion recurrence after EMR for large colorectal LSLs. The hypothesis is that performing complete defect closure following EMR of large colorectal LSLs will result in lower rates of adverse events compared to cases where no defect closure is performed. For participants with planned EMR, endoscopists will perform EMRs as per standard of care and: * prophylactic defect closure will either not be performed (control group), or will be performed (experimental group); * then, patients will be called between 14 and 44 days after EMR to assess for possible adverse events, and electronic medical files will be verified for emergency room visits and healthcare received for an adverse event; * finally, patients will undergo follow-up colonoscopy 6 months and 18 months after randomization.	Cancer	Non applicable	À vérifier	Canada	À vérifier

Essais cliniques

8

Molécule	Indication / population	Phase	NCT	Titre	Statut
Prophylactic defect closure	Cancer	Non applicable	NCT06807073	Closure-RCT — Complete Closure After Endoscopic Mucosal Resection of Large Non-Pedunculated Colorectal Polyps	RECRUITING
Convertible Plasma Jet	Cancer	Non applicable	NCT06222788	Breast Cancer Plasma Adjuvant Intra-operative Treatment (Breast Cancer PAINT)	RECRUITING
Post-operative radiotherapy	Cancer	Phase 2	NCT06878274	RESCUE — Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC	RECRUITING
EUS-guided celiac plexus neurolysis	Cancer	Phase 3	NCT00974948	Trial of Endoscopic Ultrasound (EUS) - Guided Celiac Plexus Neurolysis	COMPLETED
Radiotherapy	Cancer	À vérifier	NCT04115267	Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies	RECRUITING
SBRT	Cancer	Phase 1/2	NCT03283605	Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas	COMPLETED
Standard-of-care surgery	Cancer	Phase 1	NCT06743555	SAVED LUNG — Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study	NOT_YET_RECRUITING
Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients	Sclérose latérale amyotrophique	Non applicable	NCT06051123	Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients	RECRUITING

Publications

6

Molécule	Indication / population	Titre	Journal	Date
Convertible Plasma Jet		Nonthermal plasma jet mitigates viral replication and inflammation in human coronavirus 229E-infected lung cells by targeting the NF-κB and MAPK pathways.	Microbial pathogenesis
Convertible Plasma Jet		The CYP152-family P450 enzyme CypC of Bacillus subtilis converts non-natural substrates in plasma-driven biocatalysis.	Applied microbiology and biotechnology
Convertible Plasma Jet		An Aerosol Jet-Printed Wearable Graphene/Cellulose Nanocrystal Acoustic Sensor for Speech Recognition.	ACS sensors
Standard-of-care surgery		[F]FDG-PET/CT's change in total lesion glycolysis can accurately identify early response upon neoadjuvant immunotherapy prior to curative-intent surgery in cutaneous squamous cell carcinoma; MATISSE trial.	European journal of nuclear medicine and molecular imaging
Standard-of-care surgery		Niacin Modulates Immune Responses in a Phase I Dose-Escalation Clinical Trial of Newly Diagnosed Glioblastoma.	Neurology(R) neuroimmunology & neuroinflammation
Standard-of-care surgery		Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies.	Journal of immunotherapy and precision oncology